Literature DB >> 6846326

Interaction of protamine sulfate with thrombin.

R J Cobel-Geard, H I Hassouna.   

Abstract

Protamine sulfate (salmine), a basic protein with a molecular weight of 4,626 +/- 109, is a known antiheparin agent which in the absence of heparin demonstrates an anticoagulant activity. To date, much work has been done to elucidate the interaction of heparin with thrombin and its physiologic inhibitor, Antithrombin III (ATIII). Little is known, however, about the mechanism of anticoagulant action of protamine sulfate and its mode of thrombin inactivation. We provide information about the interaction of protamine sulfate with purified, labeled thrombin and ATIII through binding experiments in which protamine is shown to inhibit the inactivation of thrombin by ATIII. Furthermore, we show in clotting assays that protamine sulfate has an inhibitory effect on thrombin in the conversion of fibrinogen to fibrin, and that this inhibition is concentration dependent, partial, and reversible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846326     DOI: 10.1002/ajh.2830140304

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.

Authors:  L M Lee; L C Chang; S Wrobleski; T W Wakefield; V C Yang
Journal:  AAPS PharmSci       Date:  2001

3.  Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Authors:  Manu Thomas Kalathottukaren; Libin Abraham; Piyushkumar R Kapopara; Benjamin F L Lai; Rajesh A Shenoi; Federico I Rosell; Edward M Conway; Edward L G Pryzdial; James H Morrissey; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Blood       Date:  2016-12-29       Impact factor: 22.113

4.  Periprocedural outcomes of prophylactic protamine administration for reversal of heparin after cryoballoon ablation of atrial fibrillation.

Authors:  Giulio Conte; Carlo de Asmundis; Giannis Baltogiannis; Giacomo Di Giovanni; Giuseppe Ciconte; Juan Sieira; Yukio Saitoh; Kristel Wauters; Giacomo Mugnai; Justo Julià; Ghazala Irfan; Moises Levinstein; Hugo Enrique Cotino-Moreno; Gian-Battista Chierchia; Pedro Brugada
Journal:  J Interv Card Electrophysiol       Date:  2014-06-18       Impact factor: 1.900

5.  Heparin antagonism by polyvalent display of cationic motifs on virus-like particles.

Authors:  Andrew K Udit; Chris Everett; Andrew J Gale; Jennifer Reiber Kyle; Mihri Ozkan; M G Finn
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

6.  Point-of-Care Testing of Hemostasis in Cardiac Surgery.

Authors:  Domenico Prisco; Rita Paniccia
Journal:  Thromb J       Date:  2003-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.